NuPotential LLC is developing technologies that enable cell therapy researchers to quickly and precisely develop new regenerative medicines for diseases such as Alzheimers, diabetes, severe burns, and others. The company is also working on next generation âEpi-drugsâ, compounds that can modulate epigenetic targets and their processes, initially for the treatment of cancer. Epigenetics is the study of the epigenome, a group of functionally relevant and ubiquitous genomic modifications that do not involve a change in sequence in the underlying genomeâs DNA sequence. NuPotential discovery technologies and efforts focus on the two major components of the epigenetic machinery: histone modification and DNA methylation. Many serious disease states and neurodegenerative disorders are linked to or are a result of abnormal gene expression regulated by the epigenome. The firm has identified several promising epigenetic targets and candidate molecules from which to investigate lead series compounds. These lead molecules have demonstrated high selectivity across histone and DNA methylation isoforms and promising efficacy in enzymatic and challenging in-vitro tumors models, including triple negative breast cancer cell lines, a cancer form for which there is no currently available treatments. Forthcoming R&D efforts will expand, advance and further characterize these candidates for tumor type potential, pharmaceutics and efficacy to be selected for clinical develop
